CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that it has entered into an agreement with Biomedica Foscama Group S.p.A (BFG) to distribute the INTERCEPT Blood System for plasma and platelets in Italy, with a goal of expanding the adoption of pathogen inactivation to improve blood safety. More than 200,000 platelet and over 400,000 plasma units are produced annually by Italian blood centers for transfusion. Under the agreement, BFG will be the exclusive distr
Reported by Business Wire 2 hours ago.
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that it has entered into an agreement with Biomedica Foscama Group S.p.A (BFG) to distribute the INTERCEPT Blood System for plasma and platelets in Italy, with a goal of expanding the adoption of pathogen inactivation to improve blood safety. More than 200,000 platelet and over 400,000 plasma units are produced annually by Italian blood centers for transfusion. Under the agreement, BFG will be the exclusive distr
Reported by Business Wire 2 hours ago.